Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Interest & Investment Income (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Interest & Investment Income data on record, last reported at $4.0 million in Q4 2025.

  • For Q4 2025, Interest & Investment Income rose 8.31% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $15.7 million, up 4.88%, while the annual FY2025 figure was $15.7 million, 4.88% up from the prior year.
  • Interest & Investment Income reached $4.0 million in Q4 2025 per TARS's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $4.2 million in Q2 2025 and bottomed at -$247000.0 in Q2 2022.
  • Average Interest & Investment Income over 5 years is $2.3 million, with a median of $2.8 million recorded in 2023.
  • The widest YoY moves for Interest & Investment Income: up 17625.0% in 2022, down 3628.57% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $12000.0 in 2021, then skyrocketed by 17625.0% to $2.1 million in 2022, then skyrocketed by 40.01% to $3.0 million in 2023, then grew by 22.46% to $3.6 million in 2024, then rose by 8.31% to $4.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $4.0 million in Q4 2025, $4.1 million in Q3 2025, and $4.2 million in Q2 2025.